Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
Membranous nephropathy (MN) is a frequent cause of nephrotic syndrome in adults with variable response to rituximab (RTX) therapy. By inducing B-cell depletion, rituximab reduces autoantibody production, thereby mitigating immune-mediated kidney injury. While traditional markers like proteinuria and anti-PLA2R antibodies exhibit predictive value, their limitations necessitate more robust biomarkers.
We prospectively analyzed 149 MN patients receiving RTX over 12 months. Inflammatory indices—neutrophil-to-lymphocyte ratio (NLR), monocyte-to-lymphocyte ratio (MLR), and systemic immune-inflammation index (SIRI)—together with B-cell levels were measured alongside conventional markers at baseline, 3-, and 6-months. Predictive models for 6- and 12-month remission (complete/partial) were developed using multivariate regression and receiver operating characteristic (ROC) analysis.
Non-responders exhibited persistently elevated inflammatory markers (NLR/MLR/SIRI) throughout the entire observation period. Among the three, only SIRI can independently predict the remission of MN. At 3 months, SIRI≤1.25 (OR 3.68, 95%CI 1.39-9.72) and B cells ≤0.2% (OR 2.90, 95%CI 1.00-8.35) independently predicted 6-month response. Incorporating these two newly added indicators into the traditional variable model (The levels of proteinuria, albumin and anti-PLA2R antibody at 3 months) markedly enhances prediction accuracy (area under the curve [AUC] 0.86 vs 0.81). (AUC 0.86 vs 0.81). By 6 months, only SIRI≤0.9 (OR 4.84, 95%CI 1.43 to 16.40) and albumin change (OR 1.11, 95%CI 1.03 to 1.19) predicted 12-month prognosis, as B cell/antibody levels lost significance. The prediction model incorporating SIRI also had better performance.
B lymphocyte levels constitute a robust predictive biomarker for assessing short-term therapeutic response in membranous nephropathy patients receiving rituximab therapy. Furthermore, SIRI emerges as a valuable prognostic indicator capable of predicting both short-term efficacy and long-term renal outcomes. These findings suggest that concurrent monitoring of B lymphocyte counts, and SIRI values warrants integration into standardized monitoring frameworks within clinical management protocols.
